ATE248920T1 - Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie - Google Patents

Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie

Info

Publication number
ATE248920T1
ATE248920T1 AT95920972T AT95920972T ATE248920T1 AT E248920 T1 ATE248920 T1 AT E248920T1 AT 95920972 T AT95920972 T AT 95920972T AT 95920972 T AT95920972 T AT 95920972T AT E248920 T1 ATE248920 T1 AT E248920T1
Authority
AT
Austria
Prior art keywords
viruses
recombinated
production
gene therapy
recombinant viruses
Prior art date
Application number
AT95920972T
Other languages
English (en)
Inventor
Patrick Benoit
Patrice Denefle
Michel Perricaudet
Michael R Hayden
Marion Elizabeth Suzanne Lewis
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9463811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE248920(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE248920T1 publication Critical patent/ATE248920T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95920972T 1994-06-02 1995-05-22 Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie ATE248920T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9406759A FR2720756B1 (fr) 1994-06-02 1994-06-02 Virus recombinants, préparation et utilisation en thérapie génique.
PCT/FR1995/000669 WO1995033840A1 (fr) 1994-06-02 1995-05-22 Virus recombinants, preparation et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
ATE248920T1 true ATE248920T1 (de) 2003-09-15

Family

ID=9463811

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920972T ATE248920T1 (de) 1994-06-02 1995-05-22 Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie

Country Status (14)

Country Link
US (1) US20130210898A1 (de)
EP (1) EP0763116B2 (de)
JP (1) JPH10500859A (de)
AT (1) ATE248920T1 (de)
AU (1) AU2620595A (de)
CA (1) CA2190394C (de)
DE (1) DE69531678T3 (de)
FI (1) FI120154B (de)
FR (1) FR2720756B1 (de)
IL (1) IL113978A (de)
MX (1) MX9605988A (de)
NO (1) NO964894D0 (de)
WO (1) WO1995033840A1 (de)
ZA (1) ZA954386B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5658729A (en) 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0599859A1 (de) * 1991-06-25 1994-06-08 Novo Nordisk A/S Pankreatische lipase aus säugetieren und deren varianten
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo

Also Published As

Publication number Publication date
FR2720756B1 (fr) 1996-07-12
IL113978A (en) 2006-06-11
JPH10500859A (ja) 1998-01-27
EP0763116B2 (de) 2008-04-23
ZA954386B (en) 1996-03-15
US20130210898A1 (en) 2013-08-15
AU2620595A (en) 1996-01-04
NO964894L (no) 1996-11-18
DE69531678T3 (de) 2009-01-29
FR2720756A1 (fr) 1995-12-08
DE69531678T2 (de) 2004-07-08
EP0763116A1 (de) 1997-03-19
FI120154B (fi) 2009-07-15
CA2190394C (fr) 2008-10-14
NO964894D0 (no) 1996-11-18
IL113978A0 (en) 1995-10-31
WO1995033840A1 (fr) 1995-12-14
FI964784A0 (fi) 1996-11-29
MX9605988A (es) 1997-12-31
EP0763116B1 (de) 2003-09-03
DE69531678D1 (de) 2003-10-09
FI964784L (fi) 1996-11-29
CA2190394A1 (fr) 1995-12-14

Similar Documents

Publication Publication Date Title
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
ATE383424T1 (de) Polypeptide, deren herstellung und verwendung
IL136737A0 (en) Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
GR20010300006T1 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
DE69535540D1 (de) Zusammensetzung enthaltend nukleinsäuren und kationische polymere, zubereitung und verwendung
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
DE69905170D1 (en) Thiazolopyrimidinderivate
DE69534618D1 (de) Verfahren zur herstellung rekombinanter adeno-associated viren (aav) und deren verwendung
IL124139A (en) 5-substituted derivatives of mycophenolic acid
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE69523654D1 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
ATE248920T1 (de) Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
DE69842119D1 (de) Methode zur herstellung von canine interleukin 18
EP0806477A4 (de) Rekombinante dna, hergestellt durch einbau von dna, die für ein isoform der schwerenkette von myoglobin sm1 kodiert in vektor-dna, sowie ein mikroorganismus und ein mittel gegen arteriosklerose, welche die rekombinante dna enthalten
WO1998039417A3 (de) Humane leber-zellinie
DE59106119D1 (de) Stabilisatorkombinationen und ihre Verwendung zur Herstellung von stabilisierten, schlagzähmodifizierten Polyamiden.
AU2857401A (en) Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
WO1995027063A3 (de) Rfb-retrovirusgenom

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties